England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.

Antibiotic-resistant-bacteria
A New Agreement In England Could Help Tackle Antimicrobial Resistance and Incenitivize the development of new antibiotics • Source: Alamy

Shionogi & Co. Ltd. and Pfizer Inc. have signed agreements with the National Health Service in England that will delink the payments they receive for their respective antibiotics Fetcroja (cefiderocol) and Zavicefta (ceftazidime–avibactam) from the volume of the drugs sold. The innovative subscription model that underlies the agreements is a world first and could provide a solution to stimulating more innovation in the field of developing new antibiotic and help tackle the problem of antimicrobial resistance (AMR).

In separate news, Shionogi has also signed two other agreements that will expand access to its antibiotic in 135 countries.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

EU Pharma Reform: What You Need to Know Now

 
• By Anabel Costa-Ferreira and Ian Schofield

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Nancy Test Circulable Section Geography

 
• By Brian Bossetta

This is a short description